Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
The company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 who received soquelitinib 100 mg oral twice per day and four who received placebo), with follow-up at 28 days and 58 days.Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
Corvus Pharmaceuticals, Inc. (納斯達克:CRVS) 發佈了評估soquelitinib治療中重度特應性皮炎患者的1期臨床試驗的中期數據。
The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy.
該試驗將招募64名之前未能接受一種局部或系統治療的中重度特應性皮炎患者。
These doses were selected based on the company's prior experience evaluating soquelitinib in T-cell lymphoma patients.
這些劑量是基於公司之前在t細胞淋巴瘤患者中評估soquelitinib的經驗而選擇的。
The company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 who received soquelitinib 100 mg oral twice per day and four who received placebo), with follow-up at 28 days and 58 days.
該公司正在報告試驗第一組的完整結果，第一組包括16名患者（12名接受soquelitinib 100 mg口服，每天兩次，4名接受安慰劑），隨訪時間爲28天和58天。
The mean baseline EASI and IGA scores for soquelitinib patients were 20.4 and 3.0, respectively, compared to 18.5 and 3.3 for placebo patients.
soquelitinib患者的平均基線EASI和IGA分數分別爲20.4和3.0，而安慰劑患者的分數爲18.5和3.3。
EASI scores at 28-day and 58-day follow-up demonstrate a favorable effect of soquelitinib treatment compared to placebo.
在28天和58天的隨訪中，EASI分數顯示出soquelitinib治療與安慰劑相比具有良好的效果。
The soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soquelitinib group was seen with mean EASI reduction of 69.1% (n=10) compared to mean EASI reduction of 19.1% for the placebo group.
在28天時，soquelitinib的平均EASI分數減少了55.9%（n=12），而安慰劑的平均EASI減少了27.0%。在58天時，soquelitinib組的持續改善表現爲平均EASI減少了69.1%（n=10），而安慰劑組的平均EASI減少了19.1%。
- At day 28, in the soquelitinib group, nine of 12 patients achieved EASI 50; three of 12 achieved EASI 75 and one of 12 achieved EASI 90. Three of the 12 patients achieved IGA 0 or 1. In the placebo group, two of four patients achieved EASI 50 and none achieved EASI 75, EASI 90, or IGA 0 or 1.
- At day 58, in the soquelitinib group, nine of 10 patients achieved EASI 50, four of 10 achieved EASI 75 and one of 10 achieved EASI 90. Three of 10 patients achieved IGA 0 or 1. In the placebo group, one in four patients achieved EASI 50, and no patients achieved EASI 75, EASI 90, or IGA 0 or 1.
- 在第28天，soquelitinib組中，12名患者中有9名達到了EASI 50；3名達到了EASI 75，其中1名達到了EASI 90。12名患者中有3名達到了IGA 0或1。在安慰劑組中，4名患者中有2名達到了EASI 50，且沒有患者達到EASI 75、EASI 90或IGA 0或1。
- 在第58天，索奎利替尼組中，10名患者中有9名達到了EASI 50，4名達到了EASI 75，1名達到了EASI 90。10名患者中有3名達到了IGA 0或1。在安慰劑組中，四分之一的患者達到了EASI 50，沒有患者達到了EASI 75、EASI 90或IGA 0或1。
No significant safety issues were observed. All the patients completed 28 days of dosing. One patient reported Grade 1 nausea that did not interfere with the subject receiving the full treatment course, and one patient developed COVID-19 on day 28 of treatment; that patient had an uneventful recovery.
沒有觀察到顯著的安全性問題。所有患者完成了28天的給藥。一名患者報告了1級噁心，但沒有影響患者接受完整的治療方案，另一名患者在治療第28天發展爲COVID-19；該患者無併發症恢復。
Price Action: CRVS stock is down 36.80% at $4.67 at the last check on Wednesday.
價格動態：截至週三，CRVS股票下跌36.80%，最新價格爲4.67美元。
- United Microelectronics Signs Landmark Renewable Energy Deal with Fengmiao I Offshore Wind Farm, Stock Gains
- 聯電與豐妙I號海上風電場簽署歷史性的可再生能源協議，股價上漲。
